Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
OneMedNet (ONMD) Shares Decline -31% in 30 Days After Reverse Split

OneMedNet (ONMD) Shares Decline -31% in 30 Days After Reverse Split

Key Takeaways

  • OneMedNet (ONMD) shares declined roughly 31% over the trailing 30 days, falling from about $6.33 to approximately $4.39.
  • The move followed a 1-for-10 reverse stock split completed in late September 2026, a step commonly used to address exchange minimum-bid-price listing requirements.
  • Selling pressure continued despite a run of commercial announcements, including a seven-figure multiyear data agreement and several new channel partnerships.
  • On a trailing-quarter basis, the stock has extended a broader multi-month downtrend from levels near $7 in early-to-mid July.
  • OneMedNet remains a thinly traded micro-cap with ongoing net losses and limited analyst coverage, factors that can amplify price volatility.
  • For additional detail on this ticker, investors can review Price Targets, Earnings, and Forecast data across Tickeron's dedicated pages.
  • Readers can also explore Trending AI Robots to see curated, top-performing AI trading bots.

OneMedNet's Business and Market Focus

OneMedNet Corporation operates as a healthcare software provider specializing in digital medical image management, exchange, and sharing solutions across the Americas, Europe, and the Middle East. Its main platform, iRWD, supplies regulatory-grade imaging and clinical data to pharmaceutical firms, medical device makers, contract research organizations, and AI developers. The company also runs BEAM, a medical imaging exchange platform linking hospitals, healthcare systems, imaging centers, physicians, and patients. Based in Eden Prairie, Minnesota, OneMedNet has positioned itself as a source of regulatory-grade imaging Real World Data, which supports the rising need for high-quality, compliant datasets in AI model training and clinical research. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ONMD Stock Performance Over the Past 30 Days and Quarter

Over the trailing 30 days, ONMD fell approximately 31%, declining from an adjusted closing price near $6.33 to roughly $4.39. The path was uneven, with the stock trading in the $6.50 to $7.00 range through much of September before breaking lower in late September and early October and settling near the $4.40 level. On a trailing-quarter basis, the decline is even more pronounced: shares traded near $7 in early-to-mid July and have since lost roughly 38% of their value. This reflects a sustained downtrend punctuated by brief rebounds, rather than a single-session shock. From what I see, the pattern aligns with broader market-structure influences rather than isolated events.

Factors Behind the Recent 30-Day Move

The most significant structural event of the period was a 1-for-10 reverse stock split, which took effect in late September 2026. Reverse splits of this kind are frequently implemented to lift a stock's nominal share price and satisfy exchange listing standards, but they can also introduce elevated volatility and, in some cases, renewed selling pressure as the post-split share count and float adjust. The company paired this corporate action with a steady cadence of commercial updates. In late September, OneMedNet announced a seven-figure multiyear agreement to deliver de-identified, multimodal longitudinal clinical Real World Data to a commercially scaled, AI-enabled precision medicine company. The company also signed Mediplexus as its eleventh channel partner, extending its Real World Data footprint into Korea and the Asia-Pacific region, and subsequently announced a channel partner agreement with a global pharmaceutical intelligence provider. Despite these announcements, which signaled commercial momentum, the shares continued to drift lower, suggesting that concerns around profitability, cash consumption, and the stock's thin liquidity outweighed the positive news flow in the near term. I reviewed the price action using Tickeron’s AI Trend Prediction Engine to confirm the trend.

Drivers of Performance Across the Full Quarter

The broader quarterly downtrend reflects a combination of fundamental and market-structure pressures. OneMedNet operates at an early commercial scale, with trailing twelve-month revenue in the low single-digit millions and a negative net income, meaning the business is still funding its expansion while managing cash burn. This profile tends to leave the stock sensitive to shifts in risk appetite and to any perceived financing or dilution overhang. The reverse stock split and the associated adjustments to share count added a further layer of uncertainty during the quarter. While the company's partnership activity demonstrates growing traction for its imaging Real World Data platform, the market has yet to reward that progress with sustained upward price momentum, and the stock's low trading volume has made its day-to-day moves more pronounced.

Key Variables to Monitor Going Forward

Looking ahead, the key variables for ONMD will be the pace of commercial execution and the company's path toward sustainable profitability. Investors are likely to monitor whether recent channel partnerships and data agreements convert into recurring revenue, as well as any updates on new provider-network additions and contract value. Quarterly earnings and cash-flow disclosures will remain important signals, given the company's ongoing losses and limited cash resources. Broader factors such as demand for Real World Data in AI-driven healthcare, regulatory developments affecting data privacy and compliance, and the stock's thin liquidity and low float are also worth watching. Because OneMedNet is a small-cap name with limited analyst coverage, price discovery can be volatile, and investors should weigh these risks carefully.

AI Trading Bots as Part of My Research Process

In my regular analysis workflow, I often review Tickeron's AI Trading Bots to compare automated strategies across different market conditions and timeframes. The selection includes bots with varying approaches and performance metrics, allowing me to identify those that align with specific objectives and risk levels. This has provided a useful perspective when evaluating how systematic tools might handle volatile names like ONMD.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ONMD

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


ONMD in -9.16% downward trend, sliding for three consecutive days on November 16, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONMD declined for three days, in 225 of 247 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONMD as a result. In 45 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for ONMD turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 28 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

ONMD moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.

ONMD broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +43.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 55 of 233 cases where ONMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 24%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-86.621) is very low in comparison to the industry average of (4.523). P/E Ratio (-3.024) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.105).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
6385 Old Shady Oak Road
Phone
+1 800 918-7189
Employees
24
Web
https://www.onemednet.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.